The AI revolution: how multimodal intelligence will reshape the oncology ecosystem
Abstract Multimodal artificial intelligence (MMAI) is redefining oncology by integrating heterogeneous datasets from diagnostic modalities into cohesive analytical frameworks for more accurate and personalized cancer care. We highlight MMAI applications across the patient journey and clinical research, discuss outstanding challenges, and the need for guidelines and regulatory frameworks. By converting multimodal complexity into clinically actionable insights, MMAI is poised to improve patient outcomes while reshaping the economics of global cancer care.
Authors
- Tommasa Maio
- David Ruau
- Thorsten Gutjahr
- B Griffiths (ORCID: https://orcid.org/0000-0002-8745-1861)
- T. González
- Pedram Razavi (ORCID: https://orcid.org/0000-0003-4236-0576)
- Bob T. Li (ORCID: https://orcid.org/0000-0001-6661-8733)
- David Dellamonica
- Philippe Menu (ORCID: https://orcid.org/0000-0002-1395-6410)
- Jorge S. Reis‐Filho (ORCID: https://orcid.org/0000-0003-2969-3173)
- Pablo Azcue
- Adrien Moucquot
- Amanda Remorino
- Greg Rossi
- Hassan Naqvi
- Tom Diethe
- Ross Muken
Institutions
- AstraZeneca (United Kingdom) (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Nvidia (United States) (US)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- Sophia Genetics (Switzerland) (CH)
Publication Details
- Journal
- npj Artificial Intelligence
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1038/s44387-025-00044-4
- Citations
- 2
- Primary Topic
- Radiomics and Machine Learning in Medical Imaging
- Type
- article
- Field-Weighted Citation Impact
- 2.72
Funders
- AstraZeneca